

IN-VITRO DIAGNOSTIC SPECIAL

**MED**

JULY - 01 - 2019

MEDICALTECHOUTLOOK.COM

**TECH**  
**OUTLOOK**



**COMPANY:**

DIAGAST

**WEBSITE:**

diagast.com

**KEY PERSON:**

Bruno Morino  
CEO  
Rajkumar Singh  
Strategic Marketing Director

**DESCRIPTION:**

DIAGAST aims to help healthcare institutions execute blood group determination and safe blood transfusion quickly through its innovative product range

## TOP 10 IN-VITRO DIAGNOSTIC TECHNOLOGY SOLUTION PROVIDERS - 2019

Today, In-vitro diagnostics (IVDs) presents a faster, reliable, and cost-effective means to detect and treat diseases, along with monitoring therapy responses in patients. Despite the emerging economic and industry challenges, IVDs has become an integral part of modern healthcare and drives most of the medical decisions in the world. Caregivers can derive benefits from IVDs in many ways, ranging from diagnosing health conditions and preventing diseases or sequelae to monitoring drug therapies and improving patient outcomes. IVDs holds great importance in the global healthcare industry as it helps protect the health and safety of patients by fostering the best medical services.

The rising occurrence of chronic diseases, growing geriatric population, and the popularity of personalized care are all major factors that boost the significance of IVDs. Alongside, advanced technology such as AI, cloud, and data analytics are driving the delivery of robust solutions in the IVDs space. The current shift from a centralized laboratory testing to decentralized, point-of-care testing has clearly minimized the errors in tests and has set the stage for swift and efficient diagnosis and treatment in complicated cases.

Business requirements and goals differ for each healthcare organization and choosing the right solution provider from the multitude of IVDs technology vendors in the market can be quite toilsome. To help health providers carry out this task with utmost ease, a distinguished panel comprising CEOs, CIOs, VCs, industry analysts, and MedTech Outlook's editorial board has narrowed down a list of IVDs solution providers who are on the forefront of innovative technologies and strategies.

We present to you the "Top 10 In-Vitro Diagnostic Technology Solution Providers - 2019."



# DIAGAST

## Rapid Blood Type and Antibody Screen for Blood Transfusion

**T**echnological evolution has undoubtedly helped the medical sector make great strides during the recent times, however rapid blood type and screen during emergency blood transfusion continues to be an unaccomplished goal sadly even today. Most healthcare institutions fail to ensure compatible blood transfusion to the victims of road accidents or other emergency cases within an extremely short period, leading to fatal consequences. The delay in testing of the blood for transfusion often leads to panic and stress among the medics treating the victim as well, complicating treatment further.

The current methodologies used to determine a blood type and antibody screen/crossmatch before blood transfusion aren't quite rapid and based on old technologies having bottlenecks, thus medics have no choice than to transfuse O +ve as well as O -ve groups into the blood receivers, which isn't an ideal practice as there can be further immunization. "To address these intricacies, we collaborated with trusted partners, to develop avant-garde immune-hematology solutions that ensure rapid blood group and antibody screen determination for safest blood transfusion," mentions Bruno Morino, CEO DIAGAST.

In a span of three decades since its inception, DIAGAST has carved a niche for itself in the blood transfusion sector, known for its finesse in delivering blood matching solutions by the adoption of cutting-edge technologies. "Unlike other solutions, our technology allows medics to perform blood type & antibody screen in less than 15 mins through full automation," adds Rajkumar Singh, Strategic Marketing Director, DIAGAST.

Bruno Morino mentions that one of the recent healthcare sector trends across France and many parts of Europe is the acquisition and consolidation of laboratories under a single brand umbrella. In the current climate, the healthcare realm is seeking the development of a holistic, centralized testing platform to gather samples from small and large laboratories


alike and thus significantly reduce the infrastructure cost involved in Immuno-hematology. In the wake of a common need for a testing platform and efficient blood group determination, DIAGAST devised the QWALYS® product suite fully-automated and known for high throughput are aimed at empowering healthcare institutions focused on immunohematology, provide its share of advantages. For instance, the QWALYS® 3 is known for a loading capacity of up to 160 blood samples, offering higher value for money and its simplicity.

“

we collaborate with trusted partners, to develop avant-garde immune-hematology solutions that ensure fastest blood group type & antibody screen through automation for safe blood transfusion

The firm's flagship is ONYX®, targeted at medium and small-sized healthcare enterprises. Based on DIAGAST's exclusive M-TRAP® technology, the ONYX® automated system is a derivative of the firm's five-year-long research & development and helps healthcare institutions leverage more benefits with less infrastructure and training.

Apart from ONYX® and QWALYS®, the highlight of DIAGAST's illustrious journey so far is the development of two cutting-edge technologies for which the firm bagged patents in 2004 and 2016 respectively. While QWALYS® caters to large healthcare institutions, the recently developed M-Trap® Technology caters to smaller to mid size hospitals and clinics. The advantages of this invention are its ability to deliver fastest time to result automatically, cost efficiency and robustness.

DIAGAST's manufacturing facilities have been approved by many reputed regulatory bodies such as the U.S Food & Drug Administration and many others, a fact which speaks volumes about its reliability. DIAGAST is a large group today thanks to distributor's network in over 60 countries all over the world and generates an annual turnover of around 38 Million Euros. "Our goal is to make immunohematology much simpler, save the lives of many more patients and make treatment much affordable for large and small healthcare institutions alike," concludes Morino, revealing his firm's vision for the future. 



Bruno Morino